We are pleased that clinical results from our efforts are starting to become available to medical scientists. We hope to continue increasing the flow of clinical and scientific information, thus further solidifying our position as a leading biotechnology company committed to bringing innovative new products to patients. The data also suggest that Ethyol does not interfere with the desired anti-tumor activity of chemotherapy agents whether used alone or in combination. The study also showed that on a cumulative basis, patients receiving Ethyol were able to receive twice the amount of cisplatin than the control group before the first signs of nephrotoxicity occurred. Treatment with Ethyol also reduced the number of patients who discontinued the study, or reduced or delayed their chemotherapy from 38 percent to 28 percent.
Lung cancers can be either non-small cell lung cancer and small cell lung cancer.
This is the most common, accounting for almost 80 percent of all lung cancers. According to the American Cancer Society, lung cancer will be diagnosed in an estimated 164,100 Americans, approximately 14 percent of all cancer diagnoses, and will cause approximately 156,900 deaths, accounting for 28 percent of all cancer deaths, in 2000. For the approved indications, the clinical data do not suggest that the effectiveness of cisplatin based chemotherapy regimens is altered by Ethyol. There are at present only limited data on the effects of Ethyol on the efficacy of chemotherapy in other settings. Ethyol should not be administered to patients in other settings where chemotherapy can produce a significant survival benefit or cure, except in the context of a clinical study.